TickerHumSide-by-side comparison
Merck & Co. vs Moderna
As of Nov 11, 2026, P/S is 5.4x for Merck & Co. vs 39.9x for Moderna; revenue growth is 4.9% for Merck & Co. vs 13.1% for Moderna; net margin is 3.6% for Merck & Co. vs -110.5% for Moderna; debt/equity is 1.11 for Merck & Co. vs 0.09 for Moderna.
What stands out
- Moderna carries less debt relative to equity: 0.09 vs 1.11 for Merck & Co..
Key metrics
| Metric | MRK | MRNA |
|---|---|---|
| Price | $147.18 | $248.69 |
| Market cap | $362.83B | $100.63B |
| P/E | 148.7x (#1) | — |
| P/S | 5.4x (#1) | 39.9x (#2) |
| Revenue growth | 4.9% (#2) | 13.1% (#1) |
| Operating margin | — | -116.0% (#1) |
| Net margin | 3.6% (#1) | -110.5% (#2) |
| Debt / equity | 1.11 (#2) | 0.09 (#1) |
| 1-year return | +60.9% (#1) | — |
| Research score | 50/100 (#1) | 47/100 (#2) |
Higher is better for growth, margins, one-year return and overall score; lower is better for valuation and debt ratios. Ties share a rank and missing values are excluded.
Company research
- Merck & Co., Inc. (MRK) — Drug Manufacturers—General
- Moderna, Inc. (MRNA) — Biotechnology